Status:
RECRUITING
A Study of Pyridostigmine in Postural Tachycardia Syndrome
Lead Sponsor:
Mayo Clinic
Collaborating Sponsors:
National Institute of Neurological Disorders and Stroke (NINDS)
Conditions:
Postural Tachycardia Syndrome
Eligibility:
All Genders
15-55 years
Phase:
PHASE2
Brief Summary
This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood...
Detailed Description
The study will be done at the outpatient General Clinical Research Center (GCRC) at Charlton 7 and will involve two visits. Visit 1 will take about 3 hours, and Visit 2 will occur 2 days after Visit 1...
Eligibility Criteria
Inclusion
- Diagnosis of postural tachycardia syndrome using the following criteria:
- Orthostatic heart rate increment greater than or equal to 30 beats per minute (bpm) within 5 minutes of head-up tilt.
- Symptoms of orthostatic intolerance. These include weakness, lightheadedness, blurred vision, nausea, palpitations, and difficulty with concentration and thinking.
- Both criteria must be fulfilled.
Exclusion
- Pregnant or lactating women
- Presence of failure of other organ systems or systemic illness that could affect autonomic function or the patient's ability to cooperate with the study
- Hypothyroidism or hyperthyroidism
- Clinically significant coronary artery disease
- Medications that could interfere with autonomic testing
- Previous treatment with pyridostigmine for POTS. Patients must not have taken pyridostigmine in the past month
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00409435
Start Date
October 1 2006
End Date
February 1 2026
Last Update
July 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905